Search Results
Results found for "chronic pain"
- Accelerating GPCR Drug Discovery
If you're navigating a stuck GPCR program, planning your next crucial milestone, or struggling to gain
- Structural basis of adhesion GPCR GPR110 activation by stalk peptide and G-proteins coupling
also known to be capable of self-activation via an autoproteolysis process that removes the inhibitory GAIN
- Structure-Based Discovery of Negative Allosteric Modulators of the Metabotropic Glutamate Receptor 5
The mGlu5 receptor is activated by the main excitatory neurotransmitter of the nervous central system
- In vitro assays for the functional characterization of (psychedelic) substances at the serotonin...
perception, and thought, and have the activation of serotonin (5-HT) 2A receptors (5-HT2A Rs) as a main
- Structure-Based Discovery of Negative Allosteric Modulators of the Metabotropic Glutamate Receptor 5
The mGlu5 receptor is activated by the main excitatory neurotransmitter of the nervous central system
- A robust and Efficient FRET-Based Assay for Cannabinoid Receptor Ligands Discovery.
First Synthetic Allosteric Modulator of the CB2 Receptors and Evidence of Its Efficacy for Neuropathic Pain A.; Bazin, H.; Tinel, N.; Durroux, T.; Prézeau, L.; Trinquet, E.; Pin, J.-P.
- The Imprecision Problem: Why Your GPCR Drug Discovery Program Is Off-Track Before It Even Starts
And when you chain your highest-paid scientists to repetitive admin work, you’re not solving problems That’s a chaos tax — and you’re paying it in cash, time, and morale.
- TLR4 biased small molecule modulators
Currently, attention was mainly paid to biased signaling modulators targeting G protein-coupled receptors
- A new Kunitz-type snake toxin family associated with an original mode of interaction with the...
We aimed to exploit other mamba venoms to enlarge the V2R-Kunitz peptide family and gain insight into
- Inside the New Dr. GPCR Ecosystem: Learning, Insight, and Momentum for 2026
Listeners will gain perspective on: Assay choice as strategy , not convenience.
- Target Residence Time: The Hidden Driver of In Vivo Efficacy
In This Session, You’ll Gain: ✅ Modeling tools to understand how restricted diffusion in tissues like
- The Perils and Guardrails of Modifying Signalling Proteins in Bioassays
and Gαi1, respectively (Figure 2B), as well as different coupling preferences between specific Gβγ pairs delta opioid receptors is an endogenous mechanism and therapeutic target for relief from inflammatory pain
- How GPCR Spatial Signaling Sparked a Scientific Journey
Pay attention to that. What began as a quiet obsession soon demanded a bigger stage. control localised signaling, how disease hijacks these systems, and how to target them for therapeutic gain But so did choice.
- Why “Displacement” Misleads You: Allosteric Binding Demystified
In This Session, You’ll Gain: ✅ A clear explanation of why allosteric modulators don’t displace ligands—they
- Differential binding of Δ9-tetrahydrocannabinol derivatives to type 1 cannabinoid receptors (CB1)
Introduction Cannabinoid receptors are GPCRs, and two main types exist, CB1R and CB2R.
- Why Intracellular Drugs May Hold the Key to GPCR Therapeutics
In this session, you’ll gain: ✅ A clear breakdown of how intracellular vs. extracellular receptor access
- Role of G Protein-Coupled Receptors in Hepatic Stellate Cells and Approaches to Anti-Fibrotic ...
Gaining control over disease-related events in non-alcoholic steatohepatitis (NASH), an advanced form
- Early Safety Assays: Identifying Showstoppers in GPCR Drug Discovery Pipelines Early
In this session, you’ll gain: Clarity on high-impact early safety assays and their compelling rationale Understanding of toxicological mechanisms shaping go/no-go choices Strategic insights into early identification
- Characterization of a new WHIM syndrome mutant reveals mechanistic differences in regulation of ...
While several gain-of-function mutations that lead to C-terminal truncations, frame shifts and point
- The Hidden Operating Cadence That’s Actually Driving Your Biotech
Many early-stage biotechs show the same pattern: strong scientific progress paired with an operating discipline, the organization typically shifts from “busy but slightly lost” to “focused, aligned, and gaining But what kills momentum is timing inconsistency . 👉 Without a defined decision cadence: Choices get
- How System-Level GPCR Thinking Prevents Discovery Failures
What You’ll Gain Spot false confidence early → Sensitivity differences can turn full agonists into partials
- Structural dynamics of Smoothened (SMO) in ciliary membrane and its interaction with membrane lipids
the interactions of SMO with cholesterol and other lipid molecules in the ciliary membrane, and to gain
- How GPCR Collaboration Built an Innovation Engine
Monash team built rotational PhD cohorts — students cycled through multiple groups in their first year, gaining
- Embark on a GPCR Adventure: Your Weekly Research Expedition! | Oct 21-27, 2024
Biologist Senior Scientist/Staff Scientist, Computational Chemistry GPCR Activation and Signaling A gain
- How to Use Statistical Methods to Strengthen Every GPCR Drug Discovery Decision
Gain career inspiration from Ajay’s bold questions and pivots.
- Dimerization of GPCRs: Novel insight into the role of FLNA and SSAs regulating SST2 and SST5...
receptors (SSTs) are class A GPCRs abundantly expressed in pituitary tumors where they represent the main
- Purpose-Driven Opioid Research: Catherine Demery’s Academic Path
Her choice to stay in academia isn’t about rejecting industry—it’s about embracing the freedom to chase Like many young scientists, she explored different paths and gained industry experience before realizing whether to stay in academia or move into industry, Catherine speaks with unusual clarity about her choice
- Better GPCR Drug Discovery Decisions Start With Structured Learning
What you gain: Detect scaffold liabilities early—hERG inhibition, mutagenicity, and mechanistic red flags
- Why Mastering Pharmacokinetics Fundamentals Still Defines Discovery Success Today
In This Session, You’ll Gain Clarity on how ADME governs translational success A deeper understanding in vitro permeation assays that enable early iteration Absorption failures are rarely about route choice
- Targeted Drug Design through GPCR Mutagenesis: Insights from β2AR
Deep mutational scanning, for instance, is gaining popularity as a strategy due to its ability to comprehensively




















